Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral small molecule WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The company focuses on advancing azenosertib as a monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer, with the DENALI Phase 2 trial designed to support potential accelerated approval. Zentalis also evaluates azenosertib in combination with bevacizumab as maintenance therapy in ovarian cancer through the MUIR Phase 1b trial. The company utilizes Cyclin E1 expression as a predictive biomarker to identify patients who may benefit from treatment and is working with a diagnostic partner to validate a companion diagnostic test. Zentalis exclusively owns worldwide development and commercialization rights to azenosertib and has previously maintained development collaborations with Pfizer, GSK, and Dana-Farber Cancer Institute.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage zentalis.com
Sector Healthcare IR page ir.zentalis.com/overview/default.aspx
Tags
oncology, ovarian cancer, wee1 inhibitor, small molecule, clinical-stage, biomarker-directed therapy, platinum-resistant ovarian cancer, companion diagnostics, azenosertib, ZN-c3, DENALI, ZN-c3-005, ASPENOVA, MUIR, ZN-c3-002, TETON, ZN-c3-004
Press page —

Metrics

Valuation  
Market cap $ 272.182M
Market cap (USD) $ 272.182M
P/E -1.44
PEG —
P/BV 1.33
P/S 4.04
P/OCF -2.03
P/FCF -2.03
Dividend yield —
Turnover / mcap —
Returns  
ROE -49.5%
ROI -63.5%
ROIC -53.1%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 48
Quality score -41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 67.425M — — — — —
Net profit -137.06M -165.839M -292.191M -236.806M -158.725M -117.841M -45.663M
Free cash flow -125.247M -171.081M -208.405M -166.299M -160.2M -87.583M -39.495M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 1.35 3.03 15.15 20.14 84.06 51.94 —
Price performance 12m -0.55 -0.8 -0.25 -0.76 0.62 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 140,000 417,000 4,000 — 0.00 5M 0.00
↳ YoY growth +197.9% -99.0% -100.0%
↳ 5y CAGR +104.4%
Lease liabilities (USD) — 781,000 2M 45.9M 47.3M 45.8M 42.6M 39.6M
Cash and deposits (USD) 25.2M 67.2M 55M 59.7M 43.1M 28M 33.9M 36M
Intangible assets (USD) — — 8.8M — — — — —
Right-of-use assets (USD) — 2.34M 2.52M 44.7M 42.4M 35.9M 32.5M 26.3M
Cash flow detail
Operating cash flow (USD) — -39.1M -86.8M -154M -164M -208M -171M -125M
Purchases of property, plant and equipment (USD) — -352,000 -758,000 -6.11M -2.55M -583,000 -221,000 0.00
Change in receivables (cash effect) (USD) — 777,000 -277,000 413,000 0.00 0.00 -5M 5M
Change in payables (cash effect) (USD) — 7.12M 14.3M 13.9M 15.5M 10.9M -18M -17.3M
Share buybacks (cash effect) (USD) — — — — — 0.00 0.00 -9.98M
Income taxes paid (cash effect) (USD) — -15,000 -18,000 -20,000 -12,000 -140,000 -359,000 -85,000
Share-based compensation (USD) — 617,000 23.1M 35.7M 46.8M 54.8M 67.3M 20.7M
Operating cash flow before change in receivables (USD) — -39.9M -86.5M -155M -164M -208M -166M -130M
Free cash flow (OCF - PPE - intangibles) (USD) — -39.5M -87.6M -160M -166M -208M -171M -125M
Income detail
Research and development expense (USD) — 38.4M 84.9M 176M 173M 190M 168M 107M
↳ 5y CAGR +34.3% +4.8%
Total comprehensive income (USD) — -46.4M -119M -166M -238M -289M -168M -137M
Comprehensive income to owners (USD) — -45.7M -118M -159M -238M -289M -167M -137M
Reported May 15, 2020 Mar 25, 2021 Nov 10, 2021 Feb 24, 2022 Mar 26, 2025 Mar 26, 2026 Mar 26, 2026 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC

•DENALI Part 2c enrollment scheduled to complete in November 2026, with an integrated topline readout expected in 1H 2027

•$228.9 million in cash, cash equivalents and marketable securities as of September 30, 2026 provides runway into 1H 2028 to support execution of key milestones

SAN DIEGO, November 9, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.

"Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals.

October 23, 2026

  • Download (opens in new window)

  • Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reporting

  • Median relative dose intensity was 84.6%, confirming high overall exposure to azenosertib

  • DENALI Part 1b interim analysis adds to the body of evidence supporting Cyclin E1 protein expression as a predictive biomarker for azenosertib in platinum-resistant ovarian cancer

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

"These data continue to build the body of evidence supporting azenosertib as a potential treatment in Cyclin E1-positive platinum-resistant ovarian cancer, underpinning our development approach through the ongoing registration-intended DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials. For patients with Cyclin E1-positive PROC who have limited effective treatment options, we are working to deliver something that has not existed — a targeted, oral treatment that offers more convenience and choice," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals.

"The overall survival results from DENALI Part 1b are particularly meaningful given the poor prognosis associated with Cyclin E1-positive tumors and the heavily pretreated nature of this trial patient population," said Fiona Simpkins, M.D., Professor at the University of Pennsylvania Perelman School of Medicine and Lead Investigator for the DENALI study and The GOG Foundation, Inc. (GOG-F). "The separation in median overall survival between Cyclin E1-positive and Cyclin E1-negative patients — 15.9 months versus 7.5 months — strongly supports Cyclin E1 protein expression as a clinically relevant and predictive patient selection biomarker for azenosertib. Taken together with the response data and manageable adverse events, these findings provide important evidence supporting continued development of azenosertib in this biomarker-selected population with high unmet need."

Updated DENALI Part 1b Efficacy Results
As of the May 22, 2026 data cutoff, DENALI Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression who had received between one and five prior lines of therapy, with prior bevacizumab required. This was a heavily pretreated population: 97% had received a taxane, 91% bevacizumab, 55% a PARP inhibitor, and 15% mirvetuximab soravtansine, with a median of three prior lines of therapy. Cyclin E1 status was retrospectively determined by immunohistochemistry using a proprietary cutoff, with 94 patients evaluable (Cyclin E1 IHC-positive: n=48, 51%; Cyclin E1 IHC-negative: n=46).

Overall Survival (OS):

  • Cyclin E1 IHC-positive (n=48): median OS of 15.9 months (95% CI, 8.7–21.2); 31 events had occurred (65%)
  • Cyclin E1 IHC-negative (n=46): median OS of 7.5 months (95% CI, 5.8–12.3); 34 events had occurred (74%)

Objective Response Rate (ORR) and Duration of Response (DOR):

  • ORR in response-evaluable Cyclin E1 IHC-positive patients (n=43): 37.2% (95% CI, 23.0–53.3)
  • ORR in all Cyclin E1 IHC-positive patients (n=48): 33.3% (95% CI, 20.4–48.4)
  • Median DOR: 5.5 months (95% CI, 4.5–15.9)

The updated ORR includes a patient with a confirmed response after the prior cutoff. The current median DOR of 5.5 months reflects a more mature dataset with less censoring than the prior cutoff, including two patients with particularly durable responses exceeding 15 and 20 months.

Safety
The safety profile was consistent with prior reporting. The most common treatment-related adverse events (TRAEs) were nausea, fatigue, diarrhea, thrombocytopenia, decreased appetite, anemia, and neutropenia. The most common non-hematologic Grade ≥3 TRAE was fatigue (16%). Grade ≥3 hematologic TRAEs included thrombocytopenia (12%), anemia (11%), and neutropenia (11%).

The median relative dose intensity was 84.6%, confirming that overall exposure to azenosertib remained high despite dose modifications. TRAEs led to dose interruption in 56.9% of patients, dose reduction in 43.1%, and discontinuation in 19.6%. Serious TRAEs occurred in 21.6% of patients.

The ESMO slides inclusive of the full interim analysis dataset presented at the medical meeting are available on the Zentalis website under scientific publications at the following link: https://zentalis.com/science/scientific-publications/

About the DENALI Clinical Trial
DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825, GOG-3066) studying azenosertib in patients with PROC, conducted in collaboration with The GOG Foundation, Inc. (GOG-F).

Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression, all treated at 400 mg QD 5:2 (five days of once-daily administration of azenosertib, followed by two days without azenosertib). The primary endpoint was objective response rate per RECIST v1.1; secondary endpoints included duration of response, progression-free survival, overall survival, and safety.

Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:

  • Part 2a: Dose confirmation evaluated two doses, 300 mg QD 5:2 and 400 mg QD 5:2, with approximately 30 patients enrolled per dose group. 400 mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300 mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.
  • Part 2b: Enrollment expansion at the selected 400 mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. Enrollment in this cohort is complete.
  • Part 2c: Expansion of the study population, expected to enroll approximately 40 patients previously treated with a taxane-containing regimen for PROC. This cohort is currently enrolling.

For physician and patient information about the DENALI trial, please visit www.denalitrial.com .

About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator's choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). The trial design was based on feedback from the U.S. FDA regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​

October 18, 2026

  • Download (opens in new window)

  • Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy 

  • Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026

SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026.

The published abstract reports results for OS, a secondary endpoint of DENALI Part 1b in patients with platinum-resistant ovarian cancer (PROC), from an interim analysis. As of the September 2, 2025 data cutoff:

  • In the Cyclin E1-positive subgroup (n=48): median OS of 15.8 months (95% CI, 8.7–17.8);
  • In the Cyclin E1-negative subgroup (n=46): median OS of 7.5 months (95% CI, 5.8–12.3);
  • No new safety signals were observed.

DENALI Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression who had received between one and five prior lines of therapy, with prior bevacizumab required. The primary endpoint was objective response rate; secondary endpoints included duration of response, progression-free survival, OS and safety. Cyclin E1 status was retrospectively determined by immunohistochemistry using a proprietary cutoff, with 94 patients evaluable (Cyclin E1-positive: n=48; Cyclin E1-negative: n=46).

The abstract concludes that Cyclin E1 represents a highly selective and predictive biomarker for response to azenosertib, and that median OS with azenosertib compared favorably to historical single-agent chemotherapy benchmarks in patients with Cyclin E1-positive PROC, supporting further development of azenosertib in this biomarker-selected population in the ongoing DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials.

The abstract is available on the ESMO Congress website and a rapid oral presentation is scheduled on October 23, 2026.

Presentation Details:

  • Title: "Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)"
  • Session: Rapid Oral Presentation — Gynecological Cancers: Ovarian
  • Date/Time: Friday, October 23, 2026, 4:15 p.m. – 5:45 p.m. CEST
  • Presentation Number: 1242RO
  • Location: ESMO Congress 2026, Madrid, Spain

About the DENALI Clinical Trial
DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825, GOG-3066) studying azenosertib in patients with PROC.

Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression, all treated at 400 mg QD 5:2 (five days of once-daily administration of azenosertib, followed by two days without azenosertib). The primary endpoint was objective response rate per RECIST v1.1; secondary endpoints included duration of response, progression-free survival, overall survival, and safety.

Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:

  • Part 2a: Dose confirmation evaluated two doses, 300 mg QD 5:2 and 400 mg QD 5:2, with approximately 30 patients enrolled per dose group. 400 mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300 mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.
  • Part 2b: Enrollment expansion at the selected 400 mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. Enrollment in this cohort is complete.
  • Part 2c: Broadening of the study population, which is expected to include approximately 40 patients previously treated with a taxane-containing regimen for PROC. This cohort is currently enrolling.

For physician and patient information about the DENALI trial, please visit www.denalitrial.com .

About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator's choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). The trial design was based on feedback from the U.S. FDA regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​

Prompts

Zentalis Pharmaceuticals, Inc. (ticker ZNTL), listed in United States.

Company History

Date Change Detail
Jan 8, 2020 Renamed Zeno Pharma, LLC → Zentalis Pharmaceuticals, LLC

ETFs Holding Zentalis Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.18% 170,273 $ 640.226K Aug 31, 2026
VFMO 0.06% 315,167 $ 1.185M Aug 31, 2026
FESM 0.02% 264,189 $ 1.281M Jun 30, 2026
AVSC 0.01% 144,251 $ 230.802K Nov 16, 2026
RESM 0.01% 54 $ 261.90 Jun 30, 2026
MSSM 0.00% 6,741 $ 25.346K Aug 31, 2026
DFAS 0.00% 296,786 $ 498.6K Nov 12, 2026
DCOR 0.00% 18,697 $ 31.411K Nov 12, 2026
DFAC 0.00% 15,184 $ 25.509K Nov 12, 2026